Last reviewed · How we verify
JYP0015
At a glance
| Generic name | JYP0015 |
|---|---|
| Sponsor | Guangzhou JOYO Pharma Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JYP0015 CI brief — competitive landscape report
- JYP0015 updates RSS · CI watch RSS
- Guangzhou JOYO Pharma Co., Ltd portfolio CI